Leukemia Research
Volume 36, Issue 3 , Pages 253-261 , March 2012

What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?

  • Michael W. Deininger

      Affiliations

    • Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
    • Corresponding Author InformationCorresponding author at: University of Utah, Huntsman Cancer Institute, 2000 Circle of Hope, Room 4280, Salt Lake City, Utah 84112-5550, USA. Tel.: +1 801 581 6363; fax: +1 801 585 0900.
    • ,
  • Paul Manley

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland

Received 14 July 2011 ,Revised 12 September 2011 ,Accepted 19 September 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0145-2126(11)00461-9

doi: 10.1016/j.leukres.2011.09.018

Leukemia Research
Volume 36, Issue 3 , Pages 253-261 , March 2012

Article Tools

* Image Usage & Resolution